207
Views
3
CrossRef citations to date
0
Altmetric
CLINICAL TRIAL REPORT

TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial

, , , , , ORCID Icon, , & show all
Pages 615-631 | Published online: 25 Feb 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (3)